Co-treatment of non-small cell lung carcinoma (NSCLC) cells with VEGF and vandetanib or axitinib, both VEGFR inhibitors, significantly suppresses the phosphorylation of P38 in a dose-dependent manner (55). Here, KDR is linked to non-small cell lung carcinoma.